FDA approves landmark pancreatic cancer drug that's shown to improve survival
The drug uses a new approach to block a protein that fuels tumor growth. Patients taking the drug nearly doubled their survival time in a company study.
10 sources checked · 2 source groups included · 2h ago
ABC News - Business and WCVB Boston (Hearst) describe the same event in different terms.

STILL WATCHING
As of August 27, 2026 at 12:07 AM, this is how Optics News reads the wording differences in this story.
10 sources across 2 bias buckets agree on the event.
51/99 — meaningful wording shift across the spectrum.
WHAT EACH SIDE EMPHASIZED
CBS News · Center-left · News report
WBIR10 (Tegna, Knoxville) · Center · News report
Optics keeps watching for pickup.
SEE THE HEADLINES
The drug uses a new approach to block a protein that fuels tumor growth. Patients taking the drug nearly doubled their survival time in a company study.
Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.
The Food and Drug Administration (FDA) on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms...
The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option for patients with metastatic disease. A large trial found the...
Jerrty Simonson is shown at his home earlier this year in West Valley City, Utah. Simonson has been taking daraxsonrasib as part of a clinical trial for nearly four years. His cancer is no...
In a late-stage study, Rev Med’s Rasonque helped subjects live to 13 months, nearly twice as long as those who only received chemotherapy.
WASHINGTON — The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering U.S. patients a more effective treatment against one o...
U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer
A first-of-a-kind pancreatic cancer drug given approval by the FDA on Wednesday was trialed at Dana-Farber in Boston. It offers a new approach to treating the deadly form of cancer.
Experts have hailed the drug, daraxonrasib, as a game changer for one of the world's deadliest cancers.
SOURCE MAP CHANGES
Aug 26, 10:00 PM: WBIR10 (Tegna, Knoxville) joined the source map.
Aug 26, 10:02 PM: BBC World joined the source map.
Aug 26, 10:16 PM: WCVB Boston (Hearst) joined the source map.
Aug 26, 10:18 PM: ABC News - Business joined the source map.
Now: Wording Gap is 51/99 and story health is live match · 17 sources · 2 buckets · comparable news format.